Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Why Is Ultragenyx (RARE) Up 12.4% Since Last Earnings Report?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RARE : 64.65 (-6.36%)
51.3% Return Seen to Date on SmarTrend Ultragenyx Pharm Call (RARE)

SmarTrend identified an Uptrend for Ultragenyx Pharm (NASDAQ:RARE) on January 8th, 2019 at $44.98. In approximately 2 months, Ultragenyx Pharm has returned 51.29% as of today's recent price of $68.05....

RARE : 64.65 (-6.36%)
Uptrend Call Working As Ultragenyx Pharm Stock Rises 47.9% (RARE)

SmarTrend identified an Uptrend for Ultragenyx Pharm (NASDAQ:RARE) on January 8th, 2019 at $44.98. In approximately 2 months, Ultragenyx Pharm has returned 47.91% as of today's recent price of $66.53....

RARE : 64.65 (-6.36%)
Ultragenyx to Present at Upcoming Investor Conferences

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will present...

RARE : 64.65 (-6.36%)
Ultragenyx Pharm Rises 3.16% on Heavy Volume: Watch For Potential Pullback

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $65.59 to a high of $66.75. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high...

RARE : 64.65 (-6.36%)
Ultragenyx Announces Proposed Public Offering of Common Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it has commenced...

RARE : 64.65 (-6.36%)
JPM : 99.76 (-3.02%)
Look for Shares of Ultragenyx Pharm to Potentially Pullback after Yesterday's 7.29% Rise

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $61.00 to a high of $64.68. Yesterday, the shares gained 7.3%, which took the trading range above the 3-day high...

RARE : 64.65 (-6.36%)
33.0% Return Seen to Date on SmarTrend Ultragenyx Pharm Call (RARE)

SmarTrend identified an Uptrend for Ultragenyx Pharm (NASDAQ:RARE) on January 8th, 2019 at $44.98. In approximately 2 month, Ultragenyx Pharm has returned 32.99% as of today's recent price of $59.82.

RARE : 64.65 (-6.36%)
Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients

RARE : 64.65 (-6.36%)
Report: Exploring Fundamental Drivers Behind Canopy Growth, Adobe, Ultragenyx Pharmaceutical, Humana, Ship Finance International, and NexGen Energy -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC),...

HUM : 272.60 (-1.50%)
RARE : 64.65 (-6.36%)
ADBE : 259.69 (-1.70%)
SFL : 12.12 (-2.02%)
NXGEF : 2.4274 (+4.02%)
NXE : 1.66 (-2.92%)
CGC : 44.38 (-3.61%)
Ultragenyx Pharm Rises 4.58% on Heavy Volume: Watch For Potential Pullback

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $59.41 to a high of $62.94. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high...

RARE : 64.65 (-6.36%)
Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q4

Ultragenyx (RARE) loss narrower than expected and sales beat estimates in the fourth quarter of 2018.

BAYRY : 16.6350 (-3.90%)
CELG : 88.15 (-1.65%)
RARE : 64.65 (-6.36%)
BDSI : 5.11 (-3.58%)
Ultragenyx: 4Q Earnings Snapshot

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Tuesday reported a loss of $87.8 million in its fourth quarter.

RARE : 64.65 (-6.36%)
Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results...

RARE : 64.65 (-6.36%)
Ultragenyx Pharmaceutical, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 19, 2019 / Ultragenyx Pharmaceutical, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, 2019...

RARE : 64.65 (-6.36%)
Ultragenyx Pharm Shares Up 25.5% Since SmarTrend's Buy Recommendation (RARE)

SmarTrend identified an Uptrend for Ultragenyx Pharm (NASDAQ:RARE) on January 8th, 2019 at $44.98. In approximately 1 month, Ultragenyx Pharm has returned 25.46% as of today's recent price of $56.43.

RARE : 64.65 (-6.36%)
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita(R) (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin Co. Ltd (Kyowa...

RARE : 64.65 (-6.36%)
Will Ultragenyx (RARE) Report Negative Q4 Earnings? What You Should Know

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RARE : 64.65 (-6.36%)
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host...

RARE : 64.65 (-6.36%)
16.6% Return Seen to Date on SmarTrend Ultragenyx Pharm Call (RARE)

SmarTrend identified an Uptrend for Ultragenyx Pharm (NASDAQ:RARE) on January 8th, 2019 at $44.98. In approximately 1 month, Ultragenyx Pharm has returned 16.63% as of today's recent price of $52.46.

RARE : 64.65 (-6.36%)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar